A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

Inclusion Criteria: * \- Patients older than 18 * Give written informed consent prior to any study procedures being conducted, and candidates will authorize the release and use of protected health information (PHI) * Be willing and consent to having photos taken of their fingernails * Diagnosis of chronic plaque psoriasis that has been present for at least 6 months prior to baseline * Plaque psoriasis involving at least 5% of the patient's body surface area * Nail psoriasis in at least one finger nail with a mNAPSI of 5 or greater * A Nail Pain VAS score of 4 or higher. The Nail Pain VAS will assess the severity of pain linked to the nail disease. * Must have discontinued all systemic therapies for the treatment of psoriasis or psoriatic arthritis at least 4 weeks or 5 half-lives, and biologics 2 months or 5 half-lives (whichever is longer) prior to baseline visit * Must have discontinued all topical therapies for the treatment of psoriasis at least 2 weeks prior to baseline visit * Subjects must have discontinued UV therapy at least 2 weeks prior to baseline and PUVA (psoralen ultraviolet light therapy) at least 4 weeks prior to baseline. * Subjects must be in good general health without significant uncontrolled comorbidities, other than psoriasis, as determined by the investigator based on exam findings, medical history, and clinical laboratories. Patients with stable mild renal insufficiency are eligible for enrolling in this trial. * Females of childbearing potential mus…